Si desitges distingir els teus productes, serveis o tots dos dels d'una altra empresa, és possible que necessitis una marca o nom comercial. Descobreix què són, en què consisteix el seu procediment de registri i què implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tens un nou dispositiu, producte o procediment que resolgui un problema tècnic o tingui un avantatge pràctic, existeixen diferents formis de protegir-ho a Espanya i en altres països. Descobreix com fer-ho.
La teva innovació resideix en l'estètica, l'ornamentació o l'aparença del teu producte? Protegeix-la mitjançant un disseny industrial. Descobreix quins drets confereix el registri i com realitzar la tramitació.
Els patents publicades a tot el món són una valuosa font d'informació científica, tècnica i comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Si ets emprenedor/a o una empresa i vols potenciar i millorar la rendibilitat del teu negoci protegint de forma adequada els actius intangibles de la teva organització, en aquest espai trobaràs el necessari.
131
resultados
Última actualización
09/03/2025 [07:42:00]
Resultados 25 a 50 de 131
Resumen de: US2025066302A1
Deuterated forms of volinanserin according to structural formula (I), and their pharmaceutically acceptable salts, pharmaceutical compositions containing these compounds, and methods of treatment or prevention using these compounds or pharmaceutical compositions are described. The compounds are useful for treating or preventing a disease or condition selected from psychosis, schizophrenia, schizoaffective disorder, Parkinson's disease, Lewy body dementia, sleep disorder (including insomnia), agitation, mood disorder (including depression), thromboembolic disorder, autism, and attention deficit hyperactivity disorder.
Resumen de: AU2025200812A1
Compositions and methods to prevent, inhibit or treat a disease or disorder associated with expression of APOE4 in a mammal are provided.
Resumen de: WO2025039918A1
Provided are an Akkermansia muciniphila strain, and a product and a use thereof. The Akkermansia muciniphila strain is AKK PROBIO, and the preservation number thereof is CGMCC No. 20955. The AKK PROBIO has good tolerance, high safety, a wide range of indications and a good treatment effect, and can prevent and treat diseases such as colitis, colorectal cancer, Alzheimer's disease, and gouty arthritis.
Resumen de: WO2025041080A1
Provided herein are methods of assessing selenium deficiency in subjects having Huntington's Disease. Further provided herein are methods of treating and/or preventing Huntington's Disease by administering pharmaceutical compositions comprising selenium agents.
Resumen de: WO2025041128A1
The present invention provides dihydroorotate dehydrogenase (DHODH) inhibitors which are brain permeable, and pharmaceutical compositions comprising them. The compounds and pharmaceutical compositions disclosed are useful in preventing, i.e., reducing likelihood of, delaying onset of, or treating diseases or disorders associated with neuronal hyperexcitability, e.g., diseases or disorders which can be treated by the specific inhibition of DHODH enzyme activity such as epilepsy and Alzheimer disease.
Resumen de: WO2025042769A1
Described herein are compounds that inhibit poly(ADP-ribose) polymerase (PARP) and pharmaceutical compositions comprising the same. In certain embodiments, the compounds are suitable for treating, ameliorating, and/or preventing cancer. In certain embodiments, the compounds are suitable for treating, ameliorating and/or preventing neurodegenerative diseases and/or disorders, including but not limited to Parkinson's disease, Alzheimer's disease, Lewy body dementia, Alzheimer's disease related dementia or amyotrophic lateral sclerosis.
Resumen de: WO2025042853A1
Material compositions and/or methods useful for the prophylaxis and/or treatment of a-syn protein depletion (proteinopenia) are provided, including material compositions that retain native function of a-syn protein while limiting and/or preventing amyloid formation and/or aggregation of said protein. Material compositions and formulations for enhancing protein solubility, stability, circulation time, receptor interaction, brain penetrance, CSF halflife, and for facilitating peptide/protein synthesis and purification are also provided.
Resumen de: WO2025040649A1
Described is a pharmaceutical composition comprising an antagonist/inhibitor of neuropeptide B/W receptor (NPBWR1) for use in in a method of treating, ameliorating or preventing a mood disorder/affective disorder and/or chronic stress and/or anxiety disorders and/or Parkinson's disease. Moreover, described is a pharmaceutical composition comprising an agonist/activator of neuropeptide B/W receptor (NPBWR1) for use in in a method of treating, ameliorating or preventing a bipolar affective disorder (ICD-10 F31) during the manic phase, appetitive disorders, preferably anorexia or bulimia. Further, described is a method for assessing the activity of a candidate molecule suspected of being an antagonist/inhibitor or an agonist/activator of NPBWR1.
Resumen de: EP4512415A1
The present invention relates to a CAR and to regulatory T-cells (Treg) expressing the CAR for use in the treatment of multiple sclerosis (MS) and/or Alzheimers disease (AD). The CAR, especially Treg expressing the CAR, are suitable for suppressing adverse immune reactions occurring in MS and/or AD due to the high specificity of the CAR for myelin basic protein (MBP) or myelin oligodendrocyte glycoprotein (MOG), which are primary targets of autoimmune reactions in MS and AD.
Resumen de: EP4512403A1
Described is a pharmaceutical composition comprising an antagonist/inhibitor of neuropeptide B/W receptor (NPBWR1) for use in in a method of treating, ameliorating or preventing a mood disorder/affective disorder and/or chronic stress and/or anxiety disorders and/or Parkinson's disease. Moreover, described is a pharmaceutical composition comprising an agonist/activator of neuropeptide B/W receptor (NPBWR1) for use in in a method of treating, ameliorating or preventing a bipolar affective disorder (ICD-10 F31) during the manic phase, appetitive disorders, preferably anorexia or bulimia. Further, described is a method for assessing the activity of a candidate molecule suspected of being an antagonist/inhibitor or an agonist/activator of NPBWR1.
Resumen de: EP4512413A1
Use of an interleukin 27 (IL-27) protein in preparation of a product for treating and/or delaying Alzheimer's disease (AD) is provided, belonging to the technical field of biomedicine. The IL-27 protein refers to a recombinant IL-27 protein targeting a therapeutic target II,-27, and is selected from the group consisting of a mouse-derived IL-27 protein and a human-derived IL-27 protein, as well as a mammalian IL-27 protein other than the mouse-derived IL-27 protein and the human-derived IL-27 protein. The recombinant IL-27 protein can effectively alleviate the AD caused by Aβ deposition, and can selectively bind to a target receptor, thereby ensuring an accuracy of test results. The protein receptor is highly expressed in the dentate gyrus region of hippocampus, and guarantees drug targeting to the greatest extent. The recombinant IL-27 protein also shows desirable application prospects, can quickly and effectively improve and alleviate behaviors such as the memory impairment in mice with AD, and has a clinical transformation value.
Resumen de: NL2039691A
The invention discloses the application of fibroblast growth factor 17 (FGF17) protein and/or its activators in the preparation of drugs for treating Alzheimer’s disease, belonging to the field of biomedicine technology. This invention is the first to discover that different concentrations of FGF17 can restore neuronal damage caused by Aß, including aspects such as cell viability, cell body condition, and synaptic growth. It plays a significant role in the treatment of Alzheimer’s disease and thus has the potential to become a novel protein-based drug, distinct from existing protein or antibody-based medications.
Resumen de: US2025057796A1
Disclosed is a method for the treatment of a neurological or movement disorder, e.g., Parkinson's disease, in a patient in need thereof, by parenteral administration of levodopa and a dopa decarboxylase inhibitor (DDCI), such as carbidopa, benserazide or any combination thereof.
Resumen de: AU2023301953A1
Provided in the present invention are an α,β-unsaturated amide compound, and a preparation method therefor, and a pharmaceutical composition and the use thereof. Specifically, provided in the present invention is a compound as represented by formula I, wherein the definition of each group is as described in the description. The compound can be used as a compound for improving cerebral blood flow and is used for preparing a pharmaceutical composition for treating neurodegenerative diseases such as Alzheimer's disease and vascular dementia and strokes.
Resumen de: WO2025038979A1
Material compositions and/or methods useful for the prophylaxis and/or treatment of protein depletion (proteinopenia) are provided, including material compositions that retains native function of a peptide/protein while limiting and/or preventing amyloid formation and/or aggregation of said peptide/protein. Material compositions and formulations for enhancing peptide/protein solubility, stability, circulation time, receptor interaction, brain penetrance, CSF half-life, facilitating peptide/protein synthesis and purification are also provided.
Resumen de: US2025059518A1
The compositions contain a novel aldehyde dehydrogenase derived from a novel mutant yeast, that improve memory and cognitive function. The embodiments relate to a food and pharmaceutical composition for preventing Alzheimer's disease and Huntington disease by reducing the accumulation of lesional proteins in brain tissue. The food or pharmaceutical compositions contain a lysate of any one or a mixture thereof selected from Saccharomyces cerevisiae, KCTC13925BP, KCTC14122BP, KCTC14123BP, KCTC14983BP, KCTC14984BP and KCTC14985BP.
Resumen de: US2025059233A1
Peptides and pharmaceutically acceptable salts thereof and peptide conjugates and pharmaceutically acceptable salts thereof having 5 to 15 amino acids and having an amino acid sequence comprising at least 5 consecutive amino acids from the amino acid sequence LSSTQAQQSX1 (SEQ ID NO:1) for use in treating a subject suffering from or at risk of an inflammatory disease or disorder, schizophrenia or psychosis, a neurodegenerative disease such as Parkinson's disease. Alzheimer's disease, or ALS, a gastrointestinal disease or disorder such as irritable bowel syndrome, inflammatory bowel disease. Crohn's disease, or constipation, pain (e.g., visceral pain), rheumatoid arthritis, migraine, headache, substance abuse (e.g., substance use disorder such as drug use disorder, polysubstance use disorder, alcohol use disorder, or nicotine use disorder, tobacco use disorder), drug addiction, a seizure disorder, major depressive disorder, atypical depression, a major depressive episode (MDE) (e.g., atypical MDE), treatment resistant depression, depression in the presence of a neurodegenerative disease, cognitive impairment, COVID-19 related cognitive impairment and/or depression, ADHD, an autism spectrum disorder, a pervasive developmental disorder, atypical autism, multiple sclerosis, PTSD, a sleep disorder such as insomnia, daytime fatigue, or REM sleep behavior disorder, or for use in improving sleep in a subject.
Resumen de: US2025059541A1
The disclosure relates to double stranded ribonucleic acid (dsRNAi) agents and compositions targeting a SNCA gene, particularly in a CNS tissue, as well as methods of inhibiting expression of a SNCA gene and methods of treating subjects having a SNCA-associated neurodegenerative disease or disorder, e.g., Parkinson's Disease (PD), multiple system atrophy (MSA), Lewy body dementia (LBD), among other synucleinopathies, using such dsRNAi agents and compositions.
Resumen de: AU2023321711A1
Among other things, the present disclosure provides various oligonucleotide technologies including chirally controlled oligonucleotide compositions and technologies for manufacturing such oligonucleotide compositions. In some embodiments, a method is a method of treatment or prevention of Huntington's Disease in a subject in need thereof; a method of allele-specific knockdown of a mutant Huntingtin transcript in a subject; a method for delaying the onset of and/or reducing the severity of at least one symptom of Huntington's Disease in a subject with Huntington's Disease; a method of reducing the expression, level, amount and/or activity of a mutant Huntingtin gene or a gene product thereof; and/or a method of preparation of a medicament for treatment of Huntington's Disease, wherein the method pertains to the use of an oligonucleotide described herein, administered at a dose described herein. In some embodiments, the present disclosure provides doses, dosages, and formulations of an oligonucleotide described herein.
Resumen de: WO2025036214A1
The present invention belongs to the field of gene therapy, and in particular relates to a gene therapy for treating neuropathy and a use thereof. The present invention provides a gene therapy, said gene therapy involving a recombinant nucleic acid molecule encoding human glucocerebrosidase (GCase) and a neurotrophic factor. The present invention further provides a recombinant vector comprising the recombinant nucleic acid molecule, a recombinant adeno-associated virus, a host cell and a pharmaceutical composition, which are used to treat neuropathy caused by reduced GCase activity, such as Parkinson's disease and type II and type III Gaucher's disease. It can effectively increase GCase activity and the anti-damage and anti-apoptosis abilities of neurons in a subject by means of systemic injection or local injection.
Resumen de: WO2025038296A2
Pyrvinium compounds, or a pharmaceutically acceptable salt thereof, used in methods for reducing tauopathy in a subject in need thereof. Pyrvinium compounds, or a pharmaceutically acceptable salt thereof, used in methods for treating a disease associated with accumulation of misfolded proteins (e.g., proteinopathies, Alzheimer's disease, frontotemporal dementia, Parkinson's disease, retinitis pigmentosa such as retinitis pigmentosa with rhodopsin mutations, aging, neurodegenerative diseases, or metabolic disorders).
Resumen de: EP4509504A1
The present invention aims to provide a medicament capable of treating and/or preventing diseases associated with oxidative stress by inhibiting the protein-protein interaction between Keapl and Nrf2 and activating Nrf2. The present invention relates to a compound represented by the following formula (1):wherein each symbol is as described in the DESCRIPTION,or a pharmaceutically acceptable salt thereof. In addition, the present invention also relates to a medicament containing the aforementioned compound, for the prophylaxis and/or treatment of diseases involving oxidative stress selected from the group consisting of chronic kidney disease, non-alcoholic steatohepatitis, chronic obstructive pulmonary disease, radiation skin disorder, radiation mucosal disorder, cardiac failure, pulmonary arterial hypertension, Parkinson's disease, Friedreich's ataxia, multiple sclerosis, age-related macular degeneration, retinitis pigmentosa and glaucoma.
Resumen de: WO2023201182A1
The invention relates generally to the treatment of Parkinson's Disease (PD), including Parkinson's Disease psychosis (PDP) with iloperidone.
Resumen de: WO2023201133A1
Provided are engineered cells that include a T cell receptor (TCR) or antigen-binding fragment thereof that binds to amyloid beta, and methods of engineering and using such cells, such as in methods of treatment, diagnosis, and monitoring of therapeutic effectiveness, of diseases or conditions, such as those associated with amyloid beta, e.g., Alzheimer's Disease.
Nº publicación: WO2025030991A1 13/02/2025
Solicitante:
WECARE PROBIOTICS CO LTD [CN]
\u5FAE\u5EB7\u76CA\u751F\u83CC\uFF08\u82CF\u5DDE\uFF09\u80A1\u4EFD\u6709\u9650\u516C\u53F8
Resumen de: WO2025030991A1
The present application relates to Bifidobacterium longum subsp. infantis capable of relieving Parkinson's disease and the use thereof. Said strain is named as Bifidobacterium longum subsp. infantis BI03 strain, with an accession number of CGMCC No. 24473, the preservation date thereof being March 07, 2022. Said strain can significantly relieve the symptoms of Parkinson's disease, specifically embodied in: relieving Parkinson's disease related dyskinesia and increased corticosterone levels; alleviating neuroinflammation related to Parkinson's disease; promoting glutathione and reducing brain oxidative stress injuries, etc.
BOPI
Sede Electrónica
